A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

Inclusion Criteria: * Physician diagnosis of COPD for \>12 months. * Current or former smokers with a smoking history of 10 pack-years or more. * Post-bronchodilator FEV1/ Forced Vital Capacity (FVC) ratio \<0.70 and predicted post-bronchodilator FEV1 \>30% and ≤80%. * Modified Medical Research Council dyspnea scale Grade ≥2. * Background triple therapy (Inhaled Corticosteroid \[ICS\], Long-Acting Beta Agonist \[LABA\], Long-Acting Muscarinic Antagonist \[LAMA\]) for 3 months before randomization with a stable dose of medications for 1 or more months prior to Visit 1. * Are ≥80% compliant with background therapy during the screening period. Exclusion Criteria: * Moderate or severe exacerbation of COPD within 4 weeks prior to or during the screening period. * Respiratory tract infection within 4 weeks prior to or during the screening period. * Treatment with oxygen of \>4 liters/minute. Nocturnal oxygen use for sleep apnea is allowed. * Systemic or biologic immunosuppressant therapy to treat inflammatory disease or autoimmune disease within 24 weeks or 5 half-lives prior to Visit 1, whichever is longer, with the exception of oral corticosteroids. Treatment with cyclophosphamide and rituximab within 12 months of Visit 1. * Current diagnosis of asthma according to the 2023 Global Initiative for Asthma guidelines or other accepted guidelines * History or evidence of a clinically meaningful pulmonary condition other than COPD (e.g., pulmonary fibrosis, sarcoidosis, interstitial…